This technique allows for the creation of limitless quantities of a particular antibody by fusing an antibody-producing cell with a myeloma mobile. This fusion yields hybrid cells, or hybridomas, that may be cultured to create a gradual offer of the specified monoclonal antibodies.The monoclonal antibody current market requires various important ga